Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue.

Trial Profile

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 05 May 2017

At a glance

  • Drugs PG 2 (Primary)
  • Indications Fatigue
  • Focus Therapeutic Use
  • Sponsors PhytoHealth
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 05 Jun 2009 Planned end date changed from 1 Aug 2008 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top